HB3129 amends the Illinois Controlled Substances Act to place mitragynine and 7-hydroxymitragynine, the principal alkaloids associated with kratom, into Schedule III. By doing so, the bill would treat these substances as controlled drugs under Illinois law, subjecting their possession, manufacture, delivery, and related conduct to the Act’s criminal and regulatory framework unless otherwise exempted. The bill also repeals the separate Kratom Control Act, consolidating kratom-related regulation into the state’s controlled substances law.
In practical terms, the measure would remove kratom-specific statutory treatment and replace it with a more restrictive controlled-substance classification. Because Schedule III substances are regulated under the Illinois Controlled Substances Act, the bill would affect consumers, retailers, distributors, and potentially medical or research users of kratom-derived products. The bill text does not create new exceptions or licensing provisions beyond those already available under the Controlled Substances Act.
Impact
The bill would amend Section 208 of the Illinois Controlled Substances Act to add mitragynine and 7-hydroxymitragynine to the list of Schedule III substances, making kratom’s key active compounds controlled substances in Illinois. It would also repeal the Kratom Control Act, eliminating the separate statutory scheme that currently governs kratom and folding the issue into the broader controlled-substances framework. This would likely increase enforcement authority and criminal penalties associated with these compounds, while reducing the availability of kratom products in the retail market.
Sentiment
Based on the bill text and available context, the measure appears to reflect a restrictive, enforcement-oriented approach to kratom regulation. The bill’s title and substance suggest support from sponsors concerned about public health, misuse, or unregulated sales. No committee transcript or recorded votes were provided, so there is no documented legislative debate in the supplied materials, but the proposal itself indicates an intent to tighten control rather than preserve the current kratom-specific regulatory regime.
Contention
The main point of contention is likely whether kratom should be treated as a controlled substance at all. Supporters would likely argue that scheduling mitragynine and 7-hydroxymitragynine is necessary to address safety, misuse, and inconsistent product quality, while opponents would likely argue that kratom has legitimate consumer use and that scheduling would criminalize or sharply restrict access to products many users rely on. The repeal of the Kratom Control Act is also likely to be controversial because it replaces a dedicated regulatory framework with a more punitive controlled-substances classification.